Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1680062/000114036122040544/brhc10043709_10q.htm
February 2023
February 2023
January 2023
January 2023
January 2023
December 2022
November 2022
October 2022
October 2022
September 2022
Three Months Ended September 30,
|
||||||||||||||||
GAAP
|
Non-GAAP(1)
|
|||||||||||||||
2022
|
2021
|
2022
|
2021
|
|||||||||||||
(dollars in thousands, except EPS)
|
||||||||||||||||
Revenue
|
$
|
133,709
|
$
|
67,013
|
$
|
133,709
|
$
|
67,013
|
||||||||
Gross margin
|
49.3
|
%
|
44.3
|
%
|
49.4
|
%
|
44.5
|
%
|
||||||||
Income from operations
|
$
|
31,636
|
$
|
11,795
|
$
|
33,529
|
$
|
13,073
|
||||||||
Net income attributable to ACM Research, Inc.
|
$
|
21,004
|
$
|
10,155
|
$
|
28,178
|
$
|
12,352
|
||||||||
Basic EPS
|
$
|
0.35
|
$
|
0.17
|
$
|
0.47
|
$
|
0.21
|
||||||||
Diluted EPS (2)
|
$
|
0.32
|
$
|
0.15
|
$
|
0.42
|
$
|
0.19
|
Nine Months Ended September 30,
|
||||||||||||||||
GAAP
|
Non-GAAP(1)
|
|||||||||||||||
2022
|
2021
|
2022
|
2021
|
|||||||||||||
(dollars in thousands, except EPS)
|
||||||||||||||||
Revenue
|
$
|
280,290
|
$
|
164,609
|
$
|
280,290
|
$
|
164,609
|
||||||||
Gross margin
|
46.3
|
%
|
42.2
|
%
|
46.4
|
%
|
42.3
|
%
|
||||||||
Income from operations
|
$
|
42,365
|
$
|
19,576
|
$
|
47,601
|
$
|
23,399
|
||||||||
Net income attributable to ACM Research, Inc.
|
$
|
27,454
|
$
|
22,192
|
$
|
42,252
|
$
|
24,198
|
||||||||
Basic EPS
|
$
|
0.46
|
$
|
0.39
|
$
|
0.71
|
$
|
0.42
|
||||||||
Diluted EPS (2)
|
$
|
0.41
|
$
|
0.34
|
$
|
0.64
|
$
|
0.37
|
(1)
|
Reconciliations to U.S. generally accepted accounting principles (“GAAP”) financial measures from non-GAAP financial measures are presented below under “Reconciliation of GAAP to Non-GAAP
Financial Measures.” Non-GAAP financial measures exclude stock-based compensation and, with respect to net income (loss) attributable to ACM Research, Inc. and basic and diluted earnings per share, also exclude unrealized loss on
trading securities.
|
(2)
|
Prior period results have been adjusted to reflect the three-for-one stock split effected in the form of a stock dividend in March 2022.
|
•
|
Shipments. Total shipments in the
third quarter of 2022 were $163 million, versus $99 million in the third quarter of 2021. Total shipments include deliveries for revenue in the quarter and deliveries of first tool systems awaiting customer acceptance for potential
revenue in future quarters.
|
•
|
Launched and Shipped First New Furnace Tool to China-Based Foundry Customer. In the third quarter, ACM expanded its 300mm Ultra Fn furnace dry processing platform with the introduction of its Ultra Fn A furnace tool. The Ultra Fn A system adds thermal atomic layer deposition to ACM’s
extensive list of supported furnace applications. The first Ultra Fn A furnace tool has been shipped to a top-tier China-based foundry manufacturer, and is expected to be qualified in 2023.
|
•
|
Revenue was $133.7 million, up
99.5%, reflecting an increase in revenue from single wafer cleaning, Tahoe and semi-critical cleaning, and incremental contribution from ECP, furnace and other technologies.
|
•
|
Gross margin was 49.3%, up from 44.3%.
Non-GAAP gross margin, which excludes stock-based compensation, was 49.4%, up from 44.5%. Gross margin exceeded the range of 40% to 45% reflected in the Company’s long-term business model. The Company expects gross margin to vary from
period to period due to a variety of factors, such as sales volume, product mix and favorable currency impacts from a stronger dollar versus the Chinese RMB.
|
•
|
Operating expenses were $34.3 million,
an increase of 91.9%. Non-GAAP operating expenses, which exclude the effect of stock-based compensation, were $32.6 million, up 94.8%. Operating expenses as a percent of revenue decreased to 25.7% from 26.7%. Non-GAAP operating
expenses as a percent of revenue decreased to 24.4% from 25.0%.
|
•
|
Operating income was $31.6 million, up from $11.8 million. Non-GAAP operating income, which excludes the effect of stock-based compensation, was $33.5 million, up from $13.1
million.
|
•
|
Unrealized loss on trading securities
was $5.3 million. The loss reflects the change in market value of the indirect investment by ACM Shanghai in the STAR Market IPO shares of Semiconductor Manufacturing International
Corporation (“SMIC”). The value is marked-to-market quarterly and is excluded in the non-GAAP financial metrics.
|
•
|
Realized gain from sale of trading securities was $1.1 million due to the sale of a portion of ACM Shanghai’s shares of SMIC, and which generated net proceeds of $4.5 million.
|
•
|
Other income (expense), net was $7.2
million, which reflects $6.4 million due to gains recognized from the impact of exchange rates on foreign currency-denominated working capital transactions, versus ($0.3) million.
|
•
|
Income tax expense was $10.5 million,
compared to a benefit of $0.3 million. As a result of a change in Section 174 of the U.S. Internal Revenue Code of 1986 that became effective on January 1, 2022, the effective tax rate for 2022 has increased, primarily due to a new requirement to capitalize and amortize previously deductible research and experimental
expenses. The Company’s tax provision for the nine months ended September 30, 2022 assumes the rule will not be overturned and is based on capitalization of all of its R&D expenses for tax purposes.
|
•
|
Net income attributable to ACM Research, Inc. was $21.0 million, compared to net income of $10.2 million. Non-GAAP net income attributable to ACM Research, Inc., which excludes the effect of stock-based compensation and unrealized loss on trading securities, was $28.2
million, as compared to non-GAAP net income of $12.4 million.
|
•
|
Net income per diluted share attributable to ACM Research, Inc. was $0.32, compared to $0.15. Non-GAAP net income per diluted share, which excludes the effect of stock-based compensation and unrealized loss on trading securities, was $0.42, compared to $0.19.
|
•
|
Cash and cash equivalents were $336.3
million at September 30, 2022, versus $323.7 million at June 30, 2022. Cash and cash equivalents, plus restricted cash and time deposits were $473.2 million at
September 30, 2022, versus $468.9 million at June 30, 2022.
|
In the United States:
|
The Blueshirt Group
|
|
Yujia Zhai
|
||
+1 (860) 214-0809
|
||
yujia@blueshirtgroup.com
|
||
In China:
|
The Blueshirt Group Asia
|
|
Gary Dvorchak, CFA
|
||
+86 (138) 1079-1480
|
||
gary@blueshirtgroup.com
|
September 30, 2022
|
December 31, 2021
|
|||||||
(Unaudited)
|
||||||||
(In thousands, except for par value)
|
||||||||
Assets
|
||||||||
Current assets:
|
||||||||
Cash and cash equivalents
|
$
|
336,275
|
$
|
562,548
|
||||
Restricted cash
|
367
|
519
|
||||||
Short-term time deposits
|
66,176
|
-
|
||||||
Trading securities
|
14,164
|
29,498
|
||||||
Accounts receivable
|
188,341
|
105,553
|
||||||
Income tax receivable
|
63
|
1,082
|
||||||
Other receivables
|
15,135
|
18,979
|
||||||
Inventories
|
327,792
|
218,116
|
||||||
Advances to related party
|
5,158
|
2,383
|
||||||
Prepaid expenses
|
17,771
|
14,256
|
||||||
Total current assets
|
971,242
|
952,934
|
||||||
Property, plant and equipment, net
|
66,470
|
14,042
|
||||||
Land use right, net
|
8,547
|
9,667
|
||||||
Operating lease right-of-use assets, net
|
2,647
|
4,182
|
||||||
Intangible assets, net
|
873
|
477
|
||||||
Long-term time deposits
|
70,400
|
-
|
||||||
Deferred tax assets
|
6,576
|
13,166
|
||||||
Long-term investments
|
18,538
|
12,694
|
||||||
Other long-term assets
|
2,373
|
45,017
|
||||||
Total assets
|
1,147,666
|
1,052,179
|
||||||
Liabilities and Equity
|
||||||||
Current liabilities:
|
||||||||
Short-term borrowings
|
50,688
|
9,591
|
||||||
Current portion of long-term borrowings
|
2,260
|
2,410
|
||||||
Related party accounts payable
|
6,589
|
7,899
|
||||||
Accounts payable
|
92,325
|
93,451
|
||||||
Advances from customers
|
136,610
|
52,824
|
||||||
Deferred revenue
|
4,911
|
3,180
|
||||||
Income taxes payable
|
8,564
|
254
|
||||||
FIN-48 payable
|
2,054
|
2,282
|
||||||
Other payables and accrued expenses
|
40,281
|
31,735
|
||||||
Current portion of operating lease liability
|
1,320
|
2,313
|
||||||
Total current liabilities
|
345,602
|
205,939
|
||||||
Long-term borrowings
|
18,810
|
22,957
|
||||||
Long-term operating lease liability
|
1,327
|
1,869
|
||||||
Deferred tax liability
|
1,169
|
1,302
|
||||||
Other long-term liabilities
|
6,660
|
8,447
|
||||||
Total liabilities
|
373,568
|
240,514
|
||||||
Commitments and contingencies
|
||||||||
Equity:
|
||||||||
Stockholders’ equity:
|
||||||||
Class A Common Stock
|
5
|
5
|
||||||
Class B Common Stock
|
1
|
1
|
||||||
Additional paid in capital
|
601,431
|
595,045
|
||||||
Retained earnings
|
91,186
|
63,732
|
||||||
Statutory surplus reserve
|
8,312
|
8,312
|
||||||
Accumulated other comprehensive income (loss)
|
(57,920
|
)
|
9,109
|
|||||
Total ACM Research, Inc. stockholders’ equity
|
643,015
|
676,204
|
||||||
Non-controlling interests
|
131,083
|
135,461
|
||||||
Total equity
|
774,098
|
811,665
|
||||||
Total liabilities and equity
|
$
|
1,147,666
|
$
|
1,052,179
|
Three Months Ended September 30,
|
Nine Months Ended September 30,
|
|||||||||||||||
2022
|
2021
|
2022
|
2021
|
|||||||||||||
(Unaudited)
|
(Unaudited)
|
|||||||||||||||
( In thousands, except share and per share data)
|
( In thousands, except share and per share data)
|
|||||||||||||||
Revenue
|
$
|
133,709
|
$
|
67,013
|
$
|
280,290
|
$
|
164,609
|
||||||||
Cost of revenue
|
67,742
|
37,328
|
150,480
|
95,199
|
||||||||||||
Gross profit
|
65,967
|
29,685
|
129,810
|
69,410
|
||||||||||||
Operating expenses:
|
||||||||||||||||
Sales and marketing
|
13,133
|
6,363
|
27,494
|
17,460
|
||||||||||||
Research and development
|
15,678
|
7,856
|
44,391
|
21,293
|
||||||||||||
General and administrative
|
5,520
|
3,671
|
15,560
|
11,081
|
||||||||||||
Total operating expenses,
|
34,331
|
17,890
|
87,445
|
49,834
|
||||||||||||
Income from operations
|
31,636
|
11,795
|
42,365
|
19,576
|
||||||||||||
Interest income
|
2,016
|
33
|
5,965
|
113
|
||||||||||||
Interest expense
|
(419
|
)
|
(191
|
)
|
(986
|
)
|
(574
|
)
|
||||||||
Realized gain from sale of trading securities
|
1,136
|
-
|
1,136
|
-
|
||||||||||||
Unrealized gain (loss) on trading securities
|
(5,281
|
)
|
(919
|
)
|
(9,562
|
)
|
1,817
|
|||||||||
Other income (expense), net
|
7,207
|
(255
|
)
|
9,949
|
(683
|
)
|
||||||||||
Equity income in net income of affiliates
|
1,251
|
421
|
1,652
|
1,036
|
||||||||||||
Income before income taxes
|
37,546
|
10,884
|
50,519
|
21,285
|
||||||||||||
Income tax benefit (expense)
|
(10,470
|
)
|
266
|
(14,138
|
)
|
3,021
|
||||||||||
Net income
|
27,076
|
11,150
|
36,381
|
24,306
|
||||||||||||
Less: Net income attributable to non-controlling interests
|
6,072
|
995
|
8,927
|
2,114
|
||||||||||||
Net income attributable to ACM Research, Inc.
|
$
|
21,004
|
$
|
10,155
|
$
|
27,454
|
$
|
22,192
|
||||||||
Comprehensive income:
|
||||||||||||||||
Net income
|
27,076
|
11,150
|
36,381
|
24,306
|
||||||||||||
Foreign currency translation adjustment
|
(42,416
|
)
|
(409
|
)
|
(80,334
|
)
|
1,259
|
|||||||||
Comprehensive Income (loss)
|
(15,340
|
)
|
10,741
|
(43,953
|
)
|
25,565
|
||||||||||
Less: Comprehensive income (loss) attributable to non-controlling interests and redeemable non-controlling interests
|
(1,057
|
)
|
757
|
(4,378
|
)
|
2,471
|
||||||||||
Comprehensive income (loss) attributable to ACM Research, Inc.
|
$
|
(14,283
|
)
|
$
|
9,984
|
$
|
(39,575
|
)
|
$
|
23,094
|
||||||
Net income attributable to ACM Research, Inc. per common share:
|
||||||||||||||||
Basic
|
$
|
0.35
|
$
|
0.17
|
$
|
0.46
|
$
|
0.39
|
||||||||
Diluted
|
$
|
0.32
|
$
|
0.15
|
$
|
0.41
|
$
|
0.34
|
||||||||
Weighted average common shares outstanding used in computing per share amounts:
|
||||||||||||||||
Basic
|
59,360,790
|
58,267,638
|
59,123,895
|
57,340,059
|
||||||||||||
Diluted
|
65,612,665
|
66,127,548
|
65,629,273
|
65,191,020
|
`
|
Three Months Ended September 30,
|
Nine Months Ended September 30,
|
||||||||||||||
( In thousands)
|
2022
|
2021
|
2022
|
2021
|
||||||||||||
Single wafer cleaning, Tahoe and semi-critical cleaning equipment
|
$
|
99,720
|
$
|
49,448
|
$
|
198,336
|
$
|
127,322
|
||||||||
ECP (front-end and packaging), furnace and other technologies
|
24,521
|
8,200
|
57,269
|
13,750
|
||||||||||||
Advanced packaging (excluding ECP), services & spares
|
9,468
|
9,365
|
24,685
|
23,537
|
||||||||||||
Total Revenue By Product Category
|
$
|
133,709
|
$
|
67,013
|
$
|
280,290
|
$
|
164,609
|
||||||||
Wet cleaning and other front-end processing tools
|
$
|
117,941
|
$
|
49,448
|
$
|
229,195
|
$
|
127,322
|
||||||||
Advanced packaging, other processing tools, services and spares
|
15,768
|
17,565
|
51,095
|
37,287
|
||||||||||||
Total Revenue Front-end and Back-End
|
$
|
133,709
|
$
|
67,013
|
$
|
280,290
|
$
|
164,609
|
Three Months Ended September 30,
|
Nine Months Ended September 30,
|
|||||||||||||||
2022
|
2021
|
2022
|
2021
|
|||||||||||||
Mainland China
|
$
|
131,180
|
$
|
66,887
|
$
|
273,585
|
$
|
164,319
|
||||||||
Other Regions
|
2,529
|
126
|
6,705
|
290
|
||||||||||||
$
|
133,709
|
$
|
67,013
|
$
|
280,290
|
$
|
164,609
|
Three Months Ended September 30,
|
||||||||||||||||||||||||||||||||
2022
|
2021
|
|||||||||||||||||||||||||||||||
Actual
(GAAP)
|
SBC
|
Other non-
operating
adjustments
|
Adjusted
(Non-GAAP)
|
Actual
(GAAP)
|
SBC
|
Other non-
operating
adjustments
|
Adjusted
(Non-GAAP)
|
|||||||||||||||||||||||||
(In thousands)
|
||||||||||||||||||||||||||||||||
Revenue
|
$
|
133,709
|
$
|
-
|
$
|
-
|
$
|
133,709
|
$
|
67,013
|
$
|
-
|
$
|
-
|
$
|
67,013
|
||||||||||||||||
Cost of revenue
|
(67,742
|
)
|
(130
|
)
|
-
|
(67,612
|
)
|
(37,328
|
)
|
(108
|
)
|
-
|
(37,220
|
)
|
||||||||||||||||||
Gross profit
|
65,967
|
(130
|
)
|
-
|
66,097
|
29,685
|
(108
|
)
|
-
|
29,793
|
||||||||||||||||||||||
Operating expenses:
|
||||||||||||||||||||||||||||||||
Sales and marketing
|
(13,133
|
)
|
(349
|
)
|
-
|
(12,784
|
)
|
(6,363
|
)
|
(417
|
)
|
-
|
(5,946
|
)
|
||||||||||||||||||
Research and development
|
(15,678
|
)
|
(666
|
)
|
-
|
(15,012
|
)
|
(7,856
|
)
|
(293
|
)
|
-
|
(7,563
|
)
|
||||||||||||||||||
General and administrative
|
(5,520
|
)
|
(748
|
)
|
-
|
(4,772
|
)
|
(3,671
|
)
|
(460
|
)
|
-
|
(3,211
|
)
|
||||||||||||||||||
Income (loss) from operations
|
$
|
31,636
|
$
|
(1,893
|
)
|
$
|
-
|
$
|
33,529
|
$
|
11,795
|
$
|
(1,278
|
)
|
$
|
-
|
$
|
13,073
|
||||||||||||||
Unrealized loss on trading securities
|
(5,281
|
)
|
-
|
(5,281
|
)
|
-
|
(919
|
)
|
-
|
(919
|
)
|
-
|
||||||||||||||||||||
Net income (loss) attributable to ACM Research, Inc.
|
$
|
21,004
|
$
|
(1,893
|
)
|
$
|
(5,281
|
)
|
$
|
28,178
|
$
|
10,155
|
$
|
(1,278
|
)
|
$
|
(919
|
)
|
$
|
12,352
|
||||||||||||
Basic EPS
|
$
|
0.35
|
$
|
0.47
|
$
|
0.17
|
$
|
0.21
|
||||||||||||||||||||||||
Diluted EPS
|
$
|
0.32
|
$
|
0.42
|
$
|
0.15
|
$
|
0.19
|
Nine Months Ended September 30,
|
||||||||||||||||||||||||||||||||
2022
|
2021
|
|||||||||||||||||||||||||||||||
Actual
(GAAP)
|
SBC
|
Other non-
operating
adjustments
|
Adjusted
(Non-GAAP)
|
Actual
(GAAP)
|
SBC
|
Other non-
operating
adjustments
|
Adjusted
(Non-GAAP)
|
|||||||||||||||||||||||||
(In thousands)
|
||||||||||||||||||||||||||||||||
Revenue
|
$
|
280,290
|
$
|
-
|
$
|
-
|
$
|
280,290
|
$
|
164,609
|
$
|
-
|
$
|
-
|
$
|
164,609
|
||||||||||||||||
Cost of revenue
|
(150,480
|
)
|
(383
|
)
|
-
|
(150,097
|
)
|
(95,199
|
)
|
(289
|
)
|
-
|
(94,910
|
)
|
||||||||||||||||||
Gross profit
|
129,810
|
(383
|
)
|
-
|
130,193
|
69,410
|
(289
|
)
|
-
|
69,699
|
||||||||||||||||||||||
Operating expenses:
|
||||||||||||||||||||||||||||||||
Sales and marketing
|
(27,494
|
)
|
(1,277
|
)
|
-
|
(26,217
|
)
|
(17,460
|
)
|
(1,400
|
)
|
-
|
(16,060
|
)
|
||||||||||||||||||
Research and development
|
(44,391
|
)
|
(1,733
|
)
|
-
|
(42,658
|
)
|
(21,293
|
)
|
(801
|
)
|
-
|
(20,492
|
)
|
||||||||||||||||||
General and administrative
|
(15,560
|
)
|
(1,843
|
)
|
-
|
(13,717
|
)
|
(11,081
|
)
|
(1,333
|
)
|
-
|
(9,748
|
)
|
||||||||||||||||||
Income from operations
|
$
|
42,365
|
$
|
(5,236
|
)
|
$
|
-
|
$
|
47,601
|
$
|
19,576
|
$
|
(3,823
|
)
|
$
|
-
|
$
|
23,399
|
||||||||||||||
Unrealized gain (loss) on trading securities
|
(9,562
|
)
|
-
|
(9,562
|
)
|
-
|
1,817
|
-
|
1,817
|
-
|
||||||||||||||||||||||
Net income (loss) attributable to ACM Research, Inc.
|
$
|
27,454
|
$
|
(5,236
|
)
|
$
|
(9,562
|
)
|
$
|
42,252
|
$
|
22,192
|
$
|
(3,823
|
)
|
$
|
1,817
|
$
|
24,198
|
|||||||||||||
Basic EPS
|
$
|
0.46
|
$
|
0.71
|
$
|
0.39
|
$
|
0.42
|
||||||||||||||||||||||||
Diluted EPS
|
$
|
0.41
|
$
|
0.64
|
$
|
0.34
|
$
|
0.37
|
Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1680062/000114036122040544/brhc10043709_10q.htm
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Acm Research, Inc..
Acm Research, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:
Rating
Learn More![]()
Net cash used by operations of $63.9 million during the nine months ended September 30, 2022 consisted of: Significant changes in operating asset and liability accounts included the following uses of cash: increases of inventories of $132 million (Note 5), and an increase of accounts receivable of $96.8 million (Note 4).
We have presented shipments, adjusted EBITDA, free cash flow and adjusted operating income (loss) because they are key measures used by our management and board of directors to understand and evaluate our operating performance, to establish budgets and to develop operational goals for managing our business.
We intend to retain all available funds and any future earnings to support the operation of and to finance the growth and development of our business and do not anticipate paying any cash dividends in the foreseeable future.
Research and development expense consists primarily of: compensation of personnel associated with our research and development activities, including stock based compensation; costs of components and other research and development supplies; costs of tools built for product development purposes; travel expense associated with the research of technical requirements for product development purposes and testing of concepts under consideration; amortization of costs of software used for research and development purposes; and 50 Table of Contents allocated overhead for rent and utilities.
Research and development expense consists primarily of: compensation of personnel associated with our research and development activities, including stock based compensation; costs of components and other research and development supplies; costs of tools built for product development purposes; travel expense associated with the research of technical requirements for product development purposes and testing of concepts under consideration; amortization of costs of software used for research and development purposes; and allocated overhead for rent and utilities.
64 Table of Contents Shipments,...Read more
We expect that, for the...Read more
We expect that, for the...Read more
The Lender could, however, assert...Read more
We expect that, for the...Read more
We expect that, for the...Read more
Under the Loan Agreement, ACM...Read more
? We define "adjusted EBITDA"...Read more
In particular, we believe that...Read more
Our U.S. operation includes sales,...Read more
As a result of the...Read more
Risk Factors-Regulatory Risks-The PRC's currency...Read more
Interest income (expense), net, Other...Read more
Item 1A, Risk Factors- We...Read more
Net cash provided by financing...Read more
The continuation of the COVID-19...Read more
Consistent with our methodology for...Read more
We have begun to add...Read more
The increase was driven primarily...Read more
The increase was driven primarily...Read more
The increased gross margin versus...Read more
The increased gross margin versus...Read more
Income Tax Benefit (Expense) The...Read more
Income Tax Benefit (Expense) The...Read more
Our future working capital needs...Read more
Consequences of any of those...Read more
Sales and marketing expense consists...Read more
Sales and marketing expense consists...Read more
51 Table of Contents Other...Read more
We expect gross margin to...Read more
We expect gross margin to...Read more
Accordingly, we believe that these...Read more
We have shown SAPS technology...Read more
61 Table of Contents Contractual...Read more
TEBO technology has been developed...Read more
To the extent our cash...Read more
However, if this determination proves...Read more
Although stock-based compensation is an...Read more
ACM Shanghai was certified as...Read more
ACM Shanghai was certified as...Read more
During the first six months...Read more
48 Table of Contents Comparison...Read more
53 Table of Contents Comparison...Read more
The $89.7 million decrease was...Read more
Research and development expense relates...Read more
Research and development expense relates...Read more
Our Independent Registered Public Accounting...Read more
Shipments consist of two components:...Read more
The following tables reflect the...Read more
How We Evaluate Our Operations...Read more
Interest income (expense), net, Other...Read more
46 Table of Contents Projects:...Read more
Realized gain and unrealized loss...Read more
Fluctuations vary depending on cash...Read more
The increase in our effective...Read more
The increase in our effective...Read more
Our effective tax rate differs...Read more
The significant increase from the...Read more
Government subsidies related to depreciable...Read more
We expect that, for the...Read more
We expect that, for the...Read more
Net Income Attributable to Non-Controlling...Read more
Net Income Attributable to Non-Controlling...Read more
The following summary reflects our...Read more
Equity income in net income...Read more
Cost of Revenue and Gross...Read more
Cost of Revenue and Gross...Read more
Item IA, Risk Factors- If...Read more
Other income, net primarily reflects...Read more
The dollar amount attributed to...Read more
Net Income Attributable to Non-Controlling...Read more
The total cumulative investment of...Read more
Since that time, we have...Read more
Equity income in net income...Read more
The policies began with an...Read more
For the nine months ended...Read more
The extent to which COVID-19...Read more
See "Risks Related to International...Read more
We realized $7.2 million of...Read more
We realized $9.9 million of...Read more
However, from time to time...Read more
The value of our cash,...Read more
The PRC central government may...Read more
We recorded an unrealized loss...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-Q Quarterly Report
Material Contracts, Statements, Certifications & more
Acm Research, Inc. provided additional information to their SEC Filing as exhibits
Ticker: ACMR
CIK: 1680062
Form Type: 10-Q Quarterly Report
Accession Number: 0001140361-22-040544
Submitted to the SEC: Tue Nov 08 2022 5:24:45 PM EST
Accepted by the SEC: Tue Nov 08 2022
Period: Friday, September 30, 2022
Industry: Special Industry Machinery